albuvirtide + dolutegravir

Albuvirtide + dolutegravir is a combination antiretroviral therapy for the treatment of HIV-1 infection. Albuvirtide is a long-acting peptide-based HIV-1 fusion inhibitor that binds to the gp41 subunit of the viral envelope glycoprotein, preventing fusion of the virus with host cells. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome by inhibiting HIV integrase. This combination has been studied in both treatment-naïve and treatment-experienced people living with HIV/AIDS (PLWHA), showing rapid reduction in plasma HIV RNA levels and significant improvement in immune function as measured by CD4+ T-cell counts within weeks of initiation. The regimen has demonstrated good tolerability and safety, with only limited laboratory abnormalities reported[1][5]. Albuvirtide's long half-life allows for less frequent dosing, which may benefit patients who have difficulty adhering to daily oral regimens[3]. The combination provides an alternative option for critically ill or hospitalized PLWHA, especially those with comorbidities or opportunistic infections[1][5].

Other names

ABT + DTGalbuvirtide and dolutegravir